Free Trial

Aurinia Pharmaceuticals (AUPH) Competitors

Aurinia Pharmaceuticals logo
$8.27 -0.07 (-0.84%)
Closing price 04:00 PM Eastern
Extended Trading
$8.35 +0.08 (+0.91%)
As of 06:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AUPH vs. PCVX, KRYS, CYTK, RYTM, PTCT, SRPT, RNA, SWTX, RARE, and AKRO

Should you be buying Aurinia Pharmaceuticals stock or one of its competitors? The main competitors of Aurinia Pharmaceuticals include Vaxcyte (PCVX), Krystal Biotech (KRYS), Cytokinetics (CYTK), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Sarepta Therapeutics (SRPT), Avidity Biosciences (RNA), SpringWorks Therapeutics (SWTX), Ultragenyx Pharmaceutical (RARE), and Akero Therapeutics (AKRO). These companies are all part of the "pharmaceutical products" industry.

Aurinia Pharmaceuticals vs.

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.

36.8% of Aurinia Pharmaceuticals shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 4.3% of Aurinia Pharmaceuticals shares are held by company insiders. Comparatively, 3.1% of Vaxcyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Aurinia Pharmaceuticals currently has a consensus target price of $11.50, indicating a potential upside of 38.30%. Vaxcyte has a consensus target price of $136.50, indicating a potential upside of 305.35%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Aurinia Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aurinia Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Vaxcyte
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
3.10

Aurinia Pharmaceuticals has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurinia Pharmaceuticals$247.30M4.54-$78.02M$0.2829.70
VaxcyteN/AN/A-$402.27M-$3.99-8.44

Aurinia Pharmaceuticals received 522 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.57% of users gave Vaxcyte an outperform vote while only 73.41% of users gave Aurinia Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
Aurinia PharmaceuticalsOutperform Votes
577
73.41%
Underperform Votes
209
26.59%
VaxcyteOutperform Votes
55
78.57%
Underperform Votes
15
21.43%

In the previous week, Vaxcyte had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 16 mentions for Vaxcyte and 14 mentions for Aurinia Pharmaceuticals. Vaxcyte's average media sentiment score of 1.37 beat Aurinia Pharmaceuticals' score of 0.57 indicating that Vaxcyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aurinia Pharmaceuticals
5 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Vaxcyte
15 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vaxcyte has a net margin of 0.00% compared to Aurinia Pharmaceuticals' net margin of -10.23%. Aurinia Pharmaceuticals' return on equity of -4.41% beat Vaxcyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Aurinia Pharmaceuticals-10.23% -4.41% -3.07%
Vaxcyte N/A -23.53%-22.20%

Aurinia Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500.

Summary

Vaxcyte beats Aurinia Pharmaceuticals on 11 of the 18 factors compared between the two stocks.

Get Aurinia Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AUPH vs. The Competition

MetricAurinia PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.12B$6.51B$5.35B$8.44B
Dividend YieldN/A2.64%5.21%4.11%
P/E Ratio-55.509.1526.9119.77
Price / Sales4.54259.30390.06119.10
Price / CashN/A65.8538.2534.62
Price / Book3.166.476.794.52
Net Income-$78.02M$144.21M$3.23B$248.23M
7 Day Performance2.02%2.64%1.99%0.77%
1 Month Performance5.39%4.80%11.45%13.45%
1 Year Performance50.36%-2.52%17.35%7.67%

Aurinia Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AUPH
Aurinia Pharmaceuticals
2.4198 of 5 stars
$8.27
-0.8%
$11.50
+39.1%
+49.2%$1.12B$247.30M-55.13300
PCVX
Vaxcyte
3.0946 of 5 stars
$31.59
+1.4%
$136.50
+332.1%
-53.9%$4.08BN/A-6.87160Positive News
KRYS
Krystal Biotech
4.9053 of 5 stars
$139.43
+5.5%
$218.63
+56.8%
-24.1%$4.03B$333.45M46.63210Positive News
CYTK
Cytokinetics
4.1473 of 5 stars
$32.13
+1.4%
$74.44
+131.7%
-47.9%$3.84B$19.22M-5.97250
RYTM
Rhythm Pharmaceuticals
3.9428 of 5 stars
$58.97
+2.8%
$75.38
+27.8%
+64.2%$3.75B$130.13M-13.62140Positive News
PTCT
PTC Therapeutics
4.1848 of 5 stars
$46.01
+4.0%
$61.92
+34.6%
+18.9%$3.65B$1.77B-7.751,410Gap Up
SRPT
Sarepta Therapeutics
4.8153 of 5 stars
$36.37
+0.3%
$131.22
+260.8%
-69.0%$3.57B$2.23B29.10840Analyst Forecast
High Trading Volume
RNA
Avidity Biosciences
1.9199 of 5 stars
$29.33
+5.2%
$66.38
+126.3%
+3.8%$3.53B$10.90M-10.18190Options Volume
SWTX
SpringWorks Therapeutics
2.3586 of 5 stars
$46.12
-0.3%
$52.57
+14.0%
+7.5%$3.46B$191.59M-13.25230High Trading Volume
RARE
Ultragenyx Pharmaceutical
3.9707 of 5 stars
$36.09
+2.8%
$90.93
+152.0%
-12.7%$3.39B$560.23M-5.691,310Positive News
AKRO
Akero Therapeutics
3.8137 of 5 stars
$41.53
+4.2%
$76.29
+83.7%
+138.9%$3.31BN/A-11.0730Insider Trade
High Trading Volume

Related Companies and Tools


This page (NASDAQ:AUPH) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners